Abstract
ABSTRACT In clinical development of a bioequivalent (BE) drug product, a two-step strategy is commonly adopted. In the first step, a pilot BE trial is conducted to evaluate the acceptability of the test drug product as a candidate for further evaluation in a subsequent pivotal BE trial. In the second step, a full-scale pivotal BE trial is conducted to formally establish bioequivalence. The objective and criterion of a pilot BE trial are different from those of a pivotal BE trial. In practice, however, a pilot BE trial is often inappropriately designed and analyzed based on the criterion for a pivotal BE trial. One main reason is the lack of well-established design and analysis methods for a pilot BE trial. To close this gap in practice, this study proposes a Pilot Acceptance Range method specifically constructed for analyzing a pilot BE trial within the framework of a two-step strategy. For designing a crossover pilot BE trial, this paper derives the power function and provides an easy-to-use method for determining the sample size.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
